About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
Sirtex Medical Partners with MediTrust Health to Explore Innovative Payment Models for Liver Tumor Patients in China
2024-06-28

On June 28, 2024, Grand Pharma’s Wuhan Shetai Medical Technology Co., Ltd. (Wuhan Shetai Medical) signed a partnership agreement with Shanghai Maxin Health Technology Group Co. (Shanghai Maxin Health Technology Group Co., Ltd.) (MediTrust Health), a subsidiary of WSPA, signed an agreement in Wuhan on the cooperation of MMP insurance. According to the agreement, the two parties will carry out in-depth cooperation in the field of million-dollar medical insurance.

This cooperation will further promote the integration of resources and advantages in tumor treatment, health services, insurance and innovative business models, aiming to improve the quality of life of liver tumor patients and promote the development and innovation of China’s large health industry.

Mr. Huang Wentao, General Manager of Wuhan Shetai Medical, Mr. Zhang Chu, General Manager of the Product Development Department and the Production and Financing Innovation Department of China Re Life Insurance, Mr. Feng Hao, Vice President of Magnesium Health, and Mr. Liu Jian, Chairman of Beijing Pulwell, attended the ceremony on behalf of the parties.

Prev

Next

Related news

  • Grand Pharma’s Global Innovative Ophthalmic Drug CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial
    Grand Pharma’s Global Innovative Ophthalmic Drug CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial

    2025-06-05

  • Grand Pharma’s Global Innovative Product for the Treatment of Demodex Blepharitis Is Approved for Commercialization by Macao ISAF of China
    Grand Pharma’s Global Innovative Product for the Treatment of Demodex Blepharitis Is Approved for Commercialization by Macao ISAF of China

    2025-05-30

  • Update on Strategic Investment in Telix
    Update on Strategic Investment in Telix

    2025-03-01

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions